Targeting depends on a particular disease you are interested in...

I understand that it is either autoimmunity or B-cell malignancies. The very first step is to define the target population; the second step would be to define their specific surface antigens and the third step - their localization.

For instance, have a look at : http://arthritis-research.com/content/figures/ar3909-1-l.jpg

And if you want to have ready answer - look up the following publication:

"Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity" published in 2008 in the Cancer Research by Xing Du, Richard Beers, David J. FitzGerald, and Ira Pastan

hi

dear Elbay and Agnieszk.

I am very appreciative of your information,

expresiton Surface of CD19 mor than CD22 ,cellular internalization is the same ,But a study (Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity)has shown that CD 22 is better IC50 .this artical used 2 type of toxine .

final question Which is less side effect.

thanks a lot